Androstenedione conversion in lymphocytes infiltrating breast tumor tissue

Abstract

Lymphocytes infdtrating tmnor tissue are capable of androstenedione conversion, which was assessed from 3H20 release from tritium-labeled androgen precursor of estrogens 113-androstenedione. This capacity is higher in menopausal patients than in patients of reproductive age. A tendency to a positive correlation between the intensity of androstenedione conversion in lymphocytes and aromatase activity in tumor tissue is revealed. No relationship between androstenedione conversion in lymphocytes and contamination of the isolated cell suspension with tumor cells is detected.

Expression of estrogen receptors-α and -β in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy

“…Our results are consistent with published data that these preparations produce different endocrine effects [2][3][4]. The pharmacological approach confirmed the existence of functional differences between ER-α and ER-β [1,7]. These data can be used in clinical practice.…”

“…Probably, ER-β more different in tumors containing ER-α. The presence of ER-β can contribute to interruption of signaling through ER and lower induction of PR [1,7]. Neoadjuvant hormonal therapy with steroid aromatase inhibitor exemestane most significantly decreased expression of ER-α and ER-β in ER + PR + tumors.…”

“…Samples of tRNA were isolated by the guanidine thiocyanate method from 22 primary neoplasms with various receptor phenotypes and 12 tumors of treated patients. The conditions for cDNA synthesis and amplification of reverse transcription products, structure of primers, and principles for evaluation of the results were described previously [1].…”

“…This problem was studied in vitro [9,11]. A relationship exists between the number of ER-α and ER-β and intensity of estrogen synthesis in primary breast carcinoma (aromatase activity) [1]. Here we studied the ER-α/ER-β ratio in breast cancer patients receiving antiestrogens and aromatase inhibitors.…”